Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2019 3
2021 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Improvement in Skin Moisturization and Lack of Barrier Damage Following Treatment With Clascoterone Cream 1.
D Draelos Z, Kyeremateng K, Squittieri N. D Draelos Z, et al. J Drugs Dermatol. 2025 Apr 1;24(4):397-402. doi: 10.36849/JDD.8774. J Drugs Dermatol. 2025. PMID: 40196957 Clinical Trial.
BACKGROUND: Topical medications commonly prescribed for the treatment of acne vulgaris may be limited by application-site dryness, which can result in skin barrier damage. This study aimed to evaluate the effects of clascoterone cream 1% on skin barrier prope …
BACKGROUND: Topical medications commonly prescribed for the treatment of acne vulgaris may be limited by application-site d …
Clindamycin/benzoyl peroxide gel (BenzaClin): a review of its use in the management of acne.
McKeage K, Keating GM. McKeage K, et al. Am J Clin Dermatol. 2008;9(3):193-204. doi: 10.2165/00128071-200809030-00010. Am J Clin Dermatol. 2008. PMID: 18429651 Review.
The product is generally well tolerated, and the main treatment-related adverse events in clinical trials were application-site dryness, irritation, peeling, and erythema. Thus, clindamycin/benzoyl peroxide is an effective and well tolerated option for the ma …
The product is generally well tolerated, and the main treatment-related adverse events in clinical trials were application-site …
Drug Class Review: Nonsteroidal Antiinflammatory Drugs (NSAIDs): Final Update 4 Report [Internet].
Peterson K, McDonagh M, Thakurta S, Dana T, Roberts C, Chou R, Helfand M. Peterson K, et al. Portland (OR): Oregon Health & Science University; 2010 Nov. Portland (OR): Oregon Health & Science University; 2010 Nov. PMID: 21542548 Free Books & Documents. Review.
Compared with oral NSAIDs, topical diclofenac was gastroprotective but had higher risk of application site dryness. Application site reactions and withdrawals due to adverse events were higher with diclofenac 1.5% topical solution but not with d …
Compared with oral NSAIDs, topical diclofenac was gastroprotective but had higher risk of application site dryness. …
Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a preadolescent population.
Eichenfield LF, Sugarman JL, Guenin E, Harris S, Bhatt V. Eichenfield LF, et al. Pediatr Dermatol. 2019 Mar;36(2):193-199. doi: 10.1111/pde.13744. Epub 2019 Jan 18. Pediatr Dermatol. 2019. PMID: 30656753 Free PMC article. Clinical Trial.
The majority of AEs were mild and transient: most frequently were application site pain (5.6%) and application site dryness (2.8%). Local cutaneous safety and tolerability assessments were generally mild-to-moderate and improved by Week 12. ...
The majority of AEs were mild and transient: most frequently were application site pain (5.6%) and application site dryness …
Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial.
Scheffer IE, Hulihan J, Messenheimer J, Ali S, Keenan N, Griesser J, Gutterman DL, Sebree T, Sadleir LG. Scheffer IE, et al. JAMA Netw Open. 2021 Sep 1;4(9):e2123930. doi: 10.1001/jamanetworkopen.2021.23930. JAMA Netw Open. 2021. PMID: 34477852 Free PMC article. Clinical Trial.
Treatment-related AEs that occurred in at least 5% of patients were application-site dryness, application-site pain, and somnolence (each reported by 4 patients [8%]). ...
Treatment-related AEs that occurred in at least 5% of patients were application-site dryness, application-sit …
Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate or Severe Acne Vulgaris in Adult Females.
Harper JC, Baldwin H, Stein Gold L, Guenin E. Harper JC, et al. J Drugs Dermatol. 2019 Nov 1;18(11):1147-1154. J Drugs Dermatol. 2019. PMID: 31741360 Clinical Trial.
The majority of AEs were mild and transient; more frequently reported in the moderate acne population where application site pain (2.9%), and application site dryness (5.0%) were the most common, compared with one report (4.5%) of application site pain and dr …
The majority of AEs were mild and transient; more frequently reported in the moderate acne population where application site pain (2.9%), an …
Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-Severe Acne Vulgaris in an Adult and Adolescent Female Population.
Kircik LH, Baldwin H, Lain E, Guenin E, Harris S, Bhatt V. Kircik LH, et al. J Drugs Dermatol. 2019 Feb 1;18(2):178-188. J Drugs Dermatol. 2019. PMID: 30811141 Clinical Trial.
The most frequently reported treatment related AEs with tretinoin 0.05% lotion were application site pain (3.0%/5.7%), and application site dryness (4.9%/6.4%). Local cutaneous safety and tolerability assessments were generally mild-to-moderate and improved b …
The most frequently reported treatment related AEs with tretinoin 0.05% lotion were application site pain (3.0%/5.7%), and application …